Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 02, 2005 FBO #1376
SOLICITATION NOTICE

B -- Expert Slide Diagnosis

Notice Date

8/31/2005
 

Notice Type

Solicitation Notice
 

NAICS

541990 — All Other Professional, Scientific, and Technical Services
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

Reference-Number-NCI-50167-NE
 

Response Due

9/9/2005
 

Archive Date

9/24/2005
 

Description

The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB) plans to contract on a sole source basis with David Elder, Philadelphia, PA 19130-3206 for: Expert Slide Diagnoses. This contract will be for a base year plus one (1) one-year option. The acquisition is being conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 541990 and the business size standard is $6M. Background: The Genetic Epidemiology Branch is a member of the Melanoma Genetics Consortium (MGC), which is a group of familial melanoma researchers from the U.S. and several other countries. The purpose of this procurement is to provide a mechanism for the Genetic Epidemiology Branch (GEB) to have familial melanoma study pigmented lesion pathology material reviewed by an expert dermatopathologist to ensure GEB?s participation in the Melanoma Genetics Consortium. The overall objectives of the procurement are to rigorously review pigmented lesion pathology material according to Consortium criteria and to generate pathology reports containing the variables and format needed for the Consortium. The contractor shall review pigmented lesion (melanomas and moles) pathology material for the Genetic Epidemiology Branch?s study of familial melanoma and participation in the Melanoma Genetics Consortium, and report his findings to the project officer. The report shall contain a description of the biologic and pathologic features of the pigment and surrounding cells in the mole and melanoma pathology material submitted to the contractor. Contractor shall analyze the pathology material of all melanomas and moles (approximately 124 lesions) removed from GEB melanoma study participants whose data are being contributed to the MGC. Contractor shall evaluate the lesions based on a panel of variables and pathologic criteria that are required for the MGC?s data analyses. For melanomas, these criteria include type, thickness of invasion into the skin, determination of dysplasia, and several other criteria. For moles, the criteria include type, presence and degree of dysplasia, and other cellular features. Contractor shall verify the diagnoses of melanoma, dysplastic nevi or other atypical nevi on all pigmented lesions to ensure that the GEB familial melanoma study pathology data meets the format required by the MGC. Contractor shall provide GEB with attached written pathology reports and data forms of his findings within 1-2 weeks after each pathology review, depending upon their complexity. These reports and data forms shall serve the research purposes of the GEB, and ensure that the pathology review parameters and data are consistent with the criteria and format required by the MGC. Contractor is the Principal Investigator of the Melanoma Genetics Consortium grant. He is a certified specialist in dermatopathology by the American Board of Pathology. It is essential for GEB?s participation in the Melanoma Genetics Consortium to have our study participants? pathology material reviewed by the contractor to ensure that the pathology reviews and data are consistent with the criteria and format required by the Melanoma Genetics Consortium. For these analyses, it is crucial that consistency of data within the Consortium be achieved. All pigmented lesion (melanomas and moles) pathology material from members of melanoma-prone families being studied by the Genetic Epidemiology Branch must be reviewed by the Principal Investigator, the contractor, an expert pathologist, to ensure that study participants are categorized with the correct diagnoses, and that the features all of the pigmented lesions are reviewed consistently to meet the data requirements for the Consortium?s studies. Contractor is the only known source to the NCI that can successfully complete this project. This is a notice of intent not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 3:00 PM EDT on September 9, 2005. If you have any questions, please submit them in writing via electronic mail to Karen Gardner, Contract Specialist at gardnerka@mail.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered with the Central Contractor Registration (CCR) at www.ccr.gov and the online Representations and Certifications Applications (ORCA) at http://orca.bpn.gov.
 

Place of Performance

Address: Philadelphia, PA

Zip Code: 19130

Country: USA
 

Record

SN00883571-W 20050902/050831211948 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |